Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145223 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ALMNANPC1 | |
| SCHEMBL3143581 | 0.80 | MAPK1 (0.47) | SMN1; SMN2CNR1MEN1KMT2ALMNA | |
| SCHEMBL3140995 | 0.79 | ACACB (0.48) | ACACBCNR1LMNACNR2NPC1 | |
| SCHEMBL3149320 | 0.77 | SMN1; SMN2 (0.40) | ACACBSMN1; SMN2CNR1MEN1KMT2A | |
| SCHEMBL3140851 | 0.76 | CNR1 (0.47) | SMN1; SMN2CNR1MEN1KMT2ACNR2 | |
| SCHEMBL3140845 | 0.76 | CNR1 (0.47) | SMN1; SMN2CNR1MEN1KMT2ACNR2 | |
| SCHEMBL3144042 | 0.74 | TAS1R3 (0.52) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL3149771 | 0.73 | MEN1 (0.39) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL3141470 | 0.72 | CYP3A4 (0.47) | SMN1; SMN2LMNANPC1RAB9ATP53 | |
| SCHEMBL3149541 | 0.72 | ACACB (0.55) | ACACBCNR1MEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | claimed |
| EP-1768954-A4 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1768954-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006002361-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1768954-A4 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1768954-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006002361-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | ACACB 197/4885SMN1; SMN2 2637/4885CNR1 997/4885 |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD3B1 | ACACB 197/4885SMN1; SMN2 2637/4885CNR1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.